Bluebird bio (bluebird) has reaffirmed its support for a proposed acquisition by Carlyle and SK Capital after rival bidder ...

The company’s board reiterated its recommendation to instead pursue an offer from SK Capital and Carlyle that’s worth about ...

Bluebird said late Friday that Ayrmid made an unsolicited offer to buy the company in a cash-and-stock transaction with an upfront cash payment of $4.50 per share and a one-time contingent value right ...

Bluebird (Nasdaq: BLUE) said its board unanimously recommended going forward with the acquisition offer from Carlyle and SK ...

Bluebird Bio (BLUE) announced that after three weeks of engagement, including a timeline extension, Ayrmid has not submitted a binding proposal ...

Founded in 2010, bluebird has been setting the standard for gene therapy for more than a decade—first as a scientific pioneer and now as a commercial leader. bluebird has an unrivaled track ...

Ayrmid Ltd., the parent company of UK cell therapy company Gamida Cell Ltd., sent bluebird an unsolicited, nonbinding written proposal to buy the Somerville biotech for an upfront cash payment of ...

SOMERVILLE, Mass.--(BUSINESS WIRE)-- bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird”) today confirmed it has received an unsolicited non-binding written proposal ...

Bluebird said late Friday that Ayrmid made an unsolicited offer to buy the company in a cash-and-stock transaction with an upfront cash payment of $4.50 per share and a one-time contingent value right ...

Bluebird bio is still waiting on a binding takeover bid from Ayrmid Ltd., three weeks after the company said it would pay $15 million more than SK Capital and Carlyle Group offered for the gene ...